{
  "study_id": "WJOG 5108L",
  "study_title": "Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L",
  "table_name": "Table 1",
  "table_title": "Baseline Characteristics of Study Patients",
  "footnotes": [],
  "groups": [
    {
      "name": "Erlotinib",
      "n": 280,
      "type": "intervention"
    },
    {
      "name": "Gefitinib",
      "n": 279,
      "type": "intervention"
    },
    {
      "name": "All Patients",
      "n": 559,
      "type": "total"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years, median (range)",
      "standardized_name": "Age",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "numeric_median_iqr",
          "median": 67.0,
          "iqr_min": 39.0,
          "iqr_max": 85.0,
          "raw_string": "67.0 (39-85)",
          "notes": "Range is provided instead of IQR."
        },
        {
          "group_name": "Gefitinib",
          "data_type": "numeric_median_iqr",
          "median": 68.0,
          "iqr_min": 34.0,
          "iqr_max": 91.0,
          "raw_string": "68.0 (34-91)",
          "notes": "Range is provided instead of IQR."
        },
        {
          "group_name": "All Patients",
          "data_type": "numeric_median_iqr",
          "median": 67.0,
          "iqr_min": 34.0,
          "iqr_max": 91.0,
          "raw_string": "67.0 (34-91)",
          "notes": "Range is provided instead of IQR."
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.307,
        "p_value": 0.307,
        "raw_string": ".307"
      }
    },
    {
      "original_label": "< 65",
      "standardized_name": "Age Category",
      "category": "< 65 years",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 41.8,
          "raw_string": "117 (41.8)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 37.3,
          "raw_string": "104 (37.3)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 221.0,
          "percentage": 39.5,
          "raw_string": "221 (39.5)"
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.275,
        "p_value": 0.275,
        "raw_string": ".275"
      }
    },
    {
      "original_label": "≥ 65",
      "standardized_name": "Age Category",
      "category": "≥ 65 years",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Category",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 163.0,
          "percentage": 58.2,
          "raw_string": "163 (58.2)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 175.0,
          "percentage": 62.7,
          "raw_string": "175 (62.7)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 338.0,
          "percentage": 60.5,
          "raw_string": "338 (60.5)"
        }
      ]
    },
    {
      "original_label": "Performance status",
      "standardized_name": "ECOG Performance Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.028,
        "p_value": 0.028,
        "raw_string": ".028"
      }
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "0",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 50.0,
          "raw_string": "140 (50.0)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 112.0,
          "percentage": 40.1,
          "raw_string": "112 (40.1)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 252.0,
          "percentage": 45.1,
          "raw_string": "252 (45.1)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 119.0,
          "percentage": 42.5,
          "raw_string": "119 (42.5)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 150.0,
          "percentage": 53.8,
          "raw_string": "150 (53.8)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 269.0,
          "percentage": 48.1,
          "raw_string": "269 (48.1)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status",
      "category": "2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 21.0,
          "percentage": 7.5,
          "raw_string": "21 (7.5)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 6.1,
          "raw_string": "17 (6.1)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 38.0,
          "percentage": 6.8,
          "raw_string": "38 (6.8)"
        }
      ]
    },
    {
      "original_label": "Sex",
      "standardized_name": "Sex",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.963,
        "p_value": 0.963,
        "raw_string": ".963"
      }
    },
    {
      "original_label": "Male",
      "standardized_name": "Sex",
      "category": "Male",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 128.0,
          "percentage": 45.7,
          "raw_string": "128 (45.7)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 127.0,
          "percentage": 45.5,
          "raw_string": "127 (45.5)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 255.0,
          "percentage": 45.6,
          "raw_string": "255 (45.6)"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Sex",
      "category": "Female",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 152.0,
          "percentage": 54.3,
          "raw_string": "152 (54.3)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 152.0,
          "percentage": 54.5,
          "raw_string": "152 (54.5)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 304.0,
          "percentage": 54.4,
          "raw_string": "304 (54.4)"
        }
      ]
    },
    {
      "original_label": "Stage",
      "standardized_name": "Disease Stage",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.585,
        "p_value": 0.585,
        "raw_string": ".585"
      }
    },
    {
      "original_label": "IIIB",
      "standardized_name": "Disease Stage",
      "category": "IIIB",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 9.3,
          "raw_string": "26 (9.3)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 7.2,
          "raw_string": "20 (7.2)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 46.0,
          "percentage": 8.2,
          "raw_string": "46 (8.2)"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Disease Stage",
      "category": "IV",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 194.0,
          "percentage": 69.3,
          "raw_string": "194 (69.3)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 193.0,
          "percentage": 69.2,
          "raw_string": "193 (69.2)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 387.0,
          "percentage": 69.2,
          "raw_string": "387 (69.2)"
        }
      ]
    },
    {
      "original_label": "Recurrence",
      "standardized_name": "Disease Stage",
      "category": "Recurrence",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Stage",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 21.4,
          "raw_string": "60 (21.4)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 23.7,
          "raw_string": "66 (23.7)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 126.0,
          "percentage": 22.5,
          "raw_string": "126 (22.5)"
        }
      ]
    },
    {
      "original_label": "Regimen",
      "standardized_name": "Line of Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.535,
        "p_value": 0.535,
        "raw_string": ".535"
      }
    },
    {
      "original_label": "Second line",
      "standardized_name": "Line of Therapy",
      "category": "Second line",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Line of Therapy",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 193.0,
          "percentage": 68.9,
          "raw_string": "193 (68.9)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 199.0,
          "percentage": 71.3,
          "raw_string": "199 (71.3)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 392.0,
          "percentage": 70.1,
          "raw_string": "392 (70.1)"
        }
      ]
    },
    {
      "original_label": "Third line and later",
      "standardized_name": "Line of Therapy",
      "category": "Third line and later",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Line of Therapy",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 87.0,
          "percentage": 31.1,
          "raw_string": "87 (31.1)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 80.0,
          "percentage": 28.7,
          "raw_string": "80 (28.7)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 167.0,
          "percentage": 29.9,
          "raw_string": "167 (29.9)"
        }
      ]
    },
    {
      "original_label": "Smoker",
      "standardized_name": "Smoking Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.965,
        "p_value": 0.965,
        "raw_string": ".965"
      }
    },
    {
      "original_label": "Never or light",
      "standardized_name": "Smoking Status",
      "category": "Never or light",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking Status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 50.4,
          "raw_string": "141 (50.4)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 141.0,
          "percentage": 50.5,
          "raw_string": "141 (50.5)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 282.0,
          "percentage": 50.4,
          "raw_string": "282 (50.4)"
        }
      ]
    },
    {
      "original_label": "Ever",
      "standardized_name": "Smoking Status",
      "category": "Ever",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking Status",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 139.0,
          "percentage": 49.6,
          "raw_string": "139 (49.6)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 138.0,
          "percentage": 49.5,
          "raw_string": "138 (49.5)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 277.0,
          "percentage": 49.6,
          "raw_string": "277 (49.6)"
        }
      ]
    },
    {
      "original_label": "EGFR mutation (predefined)",
      "standardized_name": "EGFR Mutation Status (Predefined)",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ],
      "comparison_statistics": {
        "statistic_type": "P value",
        "statistic_value": 0.966,
        "p_value": 0.966,
        "raw_string": ".966"
      }
    },
    {
      "original_label": "Positive (L858R or Ex19del)",
      "standardized_name": "EGFR Mutation Status (Predefined)",
      "category": "Positive (L858R or Ex19del)",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Predefined)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 185.0,
          "percentage": 65.0,
          "raw_string": "185 (65.0)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 186.0,
          "percentage": 66.7,
          "raw_string": "186 (66.7)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 371.0,
          "percentage": 66.4,
          "raw_string": "371 (66.4)"
        }
      ]
    },
    {
      "original_label": "Negative (wild type, uncommon, double)",
      "standardized_name": "EGFR Mutation Status (Predefined)",
      "category": "Negative (wild type, uncommon, double)",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Predefined)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 64.0,
          "percentage": 22.9,
          "raw_string": "64 (22.9)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 64.0,
          "percentage": 22.9,
          "raw_string": "64 (22.9)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 128.0,
          "percentage": 22.9,
          "raw_string": "128 (22.9)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "EGFR Mutation Status (Predefined)",
      "category": "Unknown",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Predefined)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 11.1,
          "raw_string": "31 (11.1)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 10.4,
          "raw_string": "29 (10.4)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 10.7,
          "raw_string": "60 (10.7)"
        }
      ]
    },
    {
      "original_label": "EGFR mutation (post hoc)",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Gefitinib",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "All Patients",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Positive",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 198.0,
          "percentage": 70.7,
          "raw_string": "198 (70.7)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 203.0,
          "percentage": 72.8,
          "raw_string": "203 (72.8)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 401.0,
          "percentage": 71.7,
          "raw_string": "401 (71.7)"
        }
      ]
    },
    {
      "original_label": "Pure L858R or pure Ex19del",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Pure L858R or pure Ex19del",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 182.0,
          "percentage": 65.0,
          "raw_string": "182 (65.0)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 182.0,
          "percentage": 65.2,
          "raw_string": "182 (65.2)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 364.0,
          "percentage": 65.1,
          "raw_string": "364 (65.1)"
        }
      ]
    },
    {
      "original_label": "Double mutation",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Double mutation",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 2.1,
          "raw_string": "6 (2.1)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 2.2,
          "raw_string": "6 (2.2)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 2.1,
          "raw_string": "12 (2.1)"
        }
      ]
    },
    {
      "original_label": "Uncommon mutation",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Uncommon mutation",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 3.6,
          "raw_string": "10 (3.6)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 5.4,
          "raw_string": "15 (5.4)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 4.2,
          "raw_string": "25 (4.2)"
        }
      ]
    },
    {
      "original_label": "Wild type",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Wild type",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 18.2,
          "raw_string": "51 (18.2)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 16.8,
          "raw_string": "47 (16.8)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 98.0,
          "percentage": 17.5,
          "raw_string": "98 (17.5)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "EGFR Mutation Status (Post hoc)",
      "category": "Unknown",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "EGFR Mutation Status (Post hoc)",
      "group_data": [
        {
          "group_name": "Erlotinib",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 11.1,
          "raw_string": "31 (11.1)"
        },
        {
          "group_name": "Gefitinib",
          "data_type": "categorical_count_percentage",
          "count": 29.0,
          "percentage": 10.4,
          "raw_string": "29 (10.4)"
        },
        {
          "group_name": "All Patients",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 10.7,
          "raw_string": "60 (10.7)"
        }
      ]
    }
  ]
}